Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CEO Sells $747,375.11 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 45,767 shares of Hims & Hers Health stock in a transaction that occurred on Friday, September 20th. The shares were sold at an average price of $16.33, for a total value of $747,375.11. Following the sale, the chief executive officer now directly owns 67,015 shares in the company, valued at $1,094,354.95. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Andrew Dudum also recently made the following trade(s):

• On Tuesday, September 3rd, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.56, for a total value of $2,750,209.28.
• On Monday, August 5th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The stock was sold at an average price of $16.47, for a total value of $3,110,985.36.
• On Wednesday, July 3rd, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.75, for a total transaction of $3,919,426.00.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $17.26 on Thursday. Hims & Hers Health, Inc. has a one year low of $5.65 and a one year high of $25.74. The business’s fifty day moving average is $17.01 and its 200 day moving average is $17.13. The stock has a market capitalization of $3.71 billion, a PE ratio of -1,725.50 and a beta of 1.05.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The firm had revenue of $315.65 million for the quarter, compared to the consensus estimate of $302.43 million. During the same quarter last year, the firm posted ($0.03) EPS. The business’s quarterly revenue was up 51.8% compared to the same quarter last year. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Hims & Hers Health

Large investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its stake in shares of Hims & Hers Health by 113.1% in the 2nd quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after buying an additional 3,205,108 shares during the last quarter. Farallon Capital Management LLC lifted its holdings in Hims & Hers Health by 3,890.5% in the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after acquiring an additional 1,634,000 shares during the period. M&G Plc bought a new position in Hims & Hers Health in the first quarter valued at about $8,232,000. Healthcare of Ontario Pension Plan Trust Fund boosted its position in Hims & Hers Health by 164.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 528,142 shares of the company’s stock worth $10,663,000 after purchasing an additional 328,142 shares during the last quarter. Finally, State of Michigan Retirement System grew its stake in shares of Hims & Hers Health by 177.8% during the 2nd quarter. State of Michigan Retirement System now owns 500,000 shares of the company’s stock valued at $10,095,000 after purchasing an additional 320,000 shares during the period. Institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

HIMS has been the subject of a number of recent research reports. Needham & Company LLC assumed coverage on shares of Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target for the company. Piper Sandler reiterated a “neutral” rating and set a $18.00 target price on shares of Hims & Hers Health in a report on Tuesday, August 6th. Imperial Capital downgraded Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Truist Financial lifted their price objective on Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research note on Thursday, July 18th. Finally, TD Cowen increased their target price on Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, July 11th. Eight research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, Hims & Hers Health has an average rating of “Moderate Buy” and a consensus target price of $19.86.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.